Valuation: Bacterin International Holdings Inc

Market Cap 47.85M 42.52M 39.68M 36.17M 68.21M 4.6B 68.85M 480M 186M 2.35B 180M 176M 7.55B P/E 2026 *
-3.01x
P/E 2027 * -11.4x
Enterprise Value 47.85M 42.52M 39.68M 36.17M 68.21M 4.6B 68.85M 480M 186M 2.35B 180M 176M 7.55B EV / Sales 2026 *
0.48x
EV / Sales 2027 * 0.43x
Free-Float
84.35%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Bacterin International Holdings Inc

Manager TitleAgeSince
Chief Executive Officer 60 2019-10-06
Director of Finance/CFO 42 2022-01-02
Chief Operating Officer 40 2023-01-15
Director TitleAgeSince
Director/Board Member 65 2018-01-31
Director/Board Member 60 2019-10-29
Chairman 55 2022-08-22
Change 5-day change 1-year change 3-year change Capi.($)
-1.75%-4.16% - - 47.85M
+0.84%-3.74%-26.69%+1.85% 169B
-0.07%-2.55%-9.53%+11.07% 110B
+0.90%+1.13%-24.83%+0.58% 106B
-1.24%-0.76%-49.04%-12.75% 73.87B
-0.24%+0.69%+0.16%+72.58% 58.98B
-0.86%+2.96%+13.57%+59.50% 51.28B
-0.71%-3.82%-7.72%-31.41% 48.16B
+0.12%-0.17%-18.21%+20.29% 40.84B
-1.01%-1.45%+28.48%-9.72% 32.21B
Average -0.40%-0.86%-10.42%+12.44% 76.69B
Weighted average by Cap. +0.03%-1.30%-16.36%+10.13%

Financials

2026 *2027 *
Net sales 99.44M 88.36M 82.47M 75.16M 142M 9.56B 143M 998M 387M 4.89B 373M 365M 15.68B 110M 97.94M 91.41M 83.32M 157M 10.6B 159M 1.11B 429M 5.42B 414M 405M 17.39B
Net income -16.11M -14.32M -13.36M -12.18M -22.97M -1.55B -23.18M -162M -62.66M -792M -60.49M -59.18M -2.54B -4.25M -3.77M -3.52M -3.21M -6.06M -408M -6.11M -42.63M -16.52M -209M -15.95M -15.6M -670M
Net Debt - -
Logo Bacterin International Holdings Inc
Xtant Medical Holdings, Inc. is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. The Company's products serve the specialized needs of orthopedic and neurological surgeons, as well as trauma, foot and ankle, sports medicine, wound care surgeons including orthobiologics for the promotion of bone healing, amniotic tissue and collagen for both surgical repair and chronic wound care, implants and instrumentation for the treatment of spinal disease. Its orthobiologics products include OsteoSponge, OsteoSelect DBM Putty, OsteoSelect PLUS DBM Putty, 3Demin, OsteoFactor Pro, OsteoVive Plus, and nanOss. Its spinal implant product categories include cervical, thoracolumbar, sacroiliac joint, and interbody. The Company has exclusive United States distribution rights to Dilon's HEMOBLAST Bellows.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-